Proxy Votes Now

Home › Funds › Guggenheim › S&P Smallcap 600 Pure Growth Fund

S&P Smallcap 600 Pure Growth Fund (RYSGX) proxy voting record 2025-2026

Fund family: Guggenheim · Filed by RYDEX SERIES FUNDS (CIK 899148) · SEC series S000003768

Share classes and tickers: RYSGX (C000010446), RYWAX (C000010445), RYWCX (C000010447)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 1,083 with, 6 against, 0 abstentions (not counted as with management). Shareholder proposals: 1 FOR, 2 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with Guggenheim as a whole

The same two figures as Guggenheim’s manager page (148,731 ballot items across 82 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsGuggenheimItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)89.1%1,07291.0%135,765
Backed environmental and social shareholder proposals at US companiesn/a05.8%1,981

Where this fund voted differently from most Guggenheim funds

Each ballot item this fund voted is set against the votes of the other Guggenheim funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most Guggenheim funds on all 1,007 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 98.7% of this fund’s 1,089 such votes could be given a sector; the other 14 (1.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care24931.2%
Consumer Discretionary24520.8%
Industrials16700.0%
Finance13500.0%
Technology11710.9%
Real Estate9000.0%
Utilities2500.0%
Consumer Staples1700.0%
Telecommunications1600.0%
Miscellaneous1100.0%
Energy300.0%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections7823
Say-on-Pay1370
Audit-related1230
Compensation420
Corporate Governance123
Capital Structure50
Shareholder Rights and Defenses20
Extraordinary Transactions10

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Acadian Asset Management Inc.June 11, 2026$1M80
Clear Secure, Inc.June 10, 2026$1M130
TG Therapeutics, Inc.June 11, 2026$901,54780
ACM Research, Inc.June 10, 2026$854,34850
DXP Enterprises, Inc.June 12, 2026$807,69880
Ligand Pharmaceuticals IncorporatedJune 5, 2026$761,516110
Sphere Entertainment Co.June 10, 2026$732,12670
PTC Therapeutics, Inc.June 2, 2026$685,42560

Notable votes against management

MeetingCompanyProposalFundMgmt
June 9, 2026Etsy, Inc.Advisory vote on a stockholder proposal to govern by majority vote. Shareholder proposalAgainstFor
March 9, 2026Sanmina CorporationTo consider and vote upon the stockholder proposal entitled "Independent Board Chairman," requesting that the Board of Directors adopt a policy and amend governing documents as necessary in order that two separate people hold the office of the Chairman and the office of the CEO. Shareholder proposalAgainstFor
June 9, 2026Pacira Biosciences, Inc.Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Oliver Benton Curtis III Shareholder proposalWithholdFor
June 9, 2026Pacira Biosciences, Inc.Election of three Class III directors to our board of directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified: Company Nominees: DOMA Nominees Opposed by the Company: Eric de Armas Shareholder proposalWithholdFor
May 14, 2026Calix, Inc.To hold an advisory vote on a stockholder proposal relating to a simple majority vote. Shareholder proposalForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Funds that vote the same way

These funds reported the same votes as S&P Smallcap 600 Pure Growth Fund in the latest season, so they share this page:

Search this fund’s votes by company

1,104 ballot items at 128 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, S&P Smallcap 600 Pure Growth Fund (RYSGX) voted at 128 shareholder meetings of 128 companies, on 1,104 ballot items in all. Where management made a recommendation, the fund followed it on 99.4% of the items and voted against it 6 times. Its most frequent area of disagreement was director elections (3 of its votes against management). It voted on 6 shareholder proposals. It voted FOR the board's own proposals less often than Guggenheim's funds as a whole (89.1% against 91.0%). It voted the same way as most Guggenheim funds on every item where a comparison was possible. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of Guggenheim’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.